Thymosin Alpha 1 Trial Aims to Prevent Pancreatic Infection in Acute Pancreatitis

Acute necrotising pancreatitis (ANP) is a severe inflammatory condition of the pancreas, often leading to serious complications. One of the most life-threatening complications is infected pancreatic necrosis (IPN), where dead pancreatic tissue becomes infected, significantly increasing morbidity and mortality. Current treatments for ANP primarily focus on supportive care, and there is a critical need for effective preventative strategies against IPN. This study protocol outlines a clinical trial designed to evaluate if Thymosin alpha 1 can reduce the incidence of IPN in patients with ANP.

As this is a protocol paper for a clinical trial, no actual results or findings are available yet. The TRACE trial is currently in the design and recruitment phase, and its primary objective is to determine if Thymosin alpha 1 can significantly reduce the incidence of infected pancreatic necrosis (IPN). Secondary endpoints will include overall mortality, the development of new organ failure, length of hospital stay, and the need for surgical or interventional procedures for pancreatic necrosis. Researchers hypothesize that Thymosin alpha 1's immunomodulatory properties will lead to a measurable reduction in infection rates. > The trial is powered to detect a 20% absolute reduction in the incidence of IPN in the Thymosin alpha 1 group compared to placebo, aiming for a statistically significant outcome with p<0.05.